Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE I-2Réponse immuno-virologique et résistances virales aux traitements24. Etard JF, Laniece I, Fall MB, Cilote V, Blazejewski L, Diop K, et al.A 84-month follow up of adherence to HAART in a cohort of adultSenegalese patients. Trop Med Int Health 2007,12:1191-1198.25. Tournoud M, Etard JF, Ecochard R, DeGruttola V. Adherence toantiretroviral therapy, virological response, and time to resistance inthe Dakar cohort. Stat Med,29:14-32.26. Djoko CF, Rimoin AW, Vidal N, Tamoufe U, Wolfe ND, Butel C, etal. High HIV type 1 group M pol diversity and low rate of antiretroviralresistance mutations among the uniformed services in Kinshasa,Democratic Republic of the Congo. AIDS Res HumRetroviruses,27:323-329.27. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, etal. Virological monitoring and resistance to first-line highly activeantiretroviral therapy in adults infected with HIV-1 treated under WHOguidelines: a systematic review and meta-analysis. Lancet Infect Dis2009,9:409-417.28. Little RJA, Rubin DB. Statistical analysis with missing data: Wiley;2002.ird-00718213, version 1 - 16 Jul 201229. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, et al.Missing data on the estimation of the prevalence of accumulatedhuman immunodeficiency virus drug resistance in patients treated withantiretroviral drugs in north america. Am J Epidemiol,174:727-735.30. Turnbull B. The empirical distribution function with arbitrarilygrouped, censored and truncated data. Journal of the Royal StatisticalSociety 1976,38:290-295.31. Farrington CP. Interval censored survival data: a generalized linearmodelling approach. Stat Med 1996,15:283-292.32. Carstensen B. Regression models for interval censored survivaldata: application to HIV infection in Danish homosexual men. Stat Med1996,15:2177-2189.33. Wood SN. Generalized additive models: an introduction with R:Chapman & Hall/CRC; 2006.34. Efron B, Tibshirani R. An introduction to the bootstrap: Chapman &Hall; 1993.35. Oksendal BK. Stochastic Differential Equations: An IntroductionWith Applications: Springer; 2003.36. R Development Core Team. R: A Language and Environment forStatistical Computing. Vienna: R Foundation for Statistical Computing;2008.37. Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM,Ciaffi L, et al. Long-term safety, effectiveness and quality of a genericfixed-dose combination of nevirapine, stavudine and lamivudine. AIDS2007,21:768-771.38. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, WoodwardJ, et al. Predictors of HIV drug-resistance mutations in a largeantiretroviral-naive cohort initiating triple antiretroviral therapy. J InfectDis 2005,191:339-347.39. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B,Major JC, et al. HIV-1 drug resistance: degree of underestimation by across-sectional versus a longitudinal testing approach. J Infect Dis2005,191:1325-1330.40. Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, EvansB. Estimating HIV-1 drug resistance in antiretroviral-treated individualsin the United Kingdom. J Infect Dis 2005,192:967-973.41. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM,et al. Long term probability of detection of HIV-1 drug resistance afterstarting antiretroviral therapy in routine clinical practice. AIDS2005,19:487-494.42. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology:Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.26